More encouraging news on the vaccine front. Here is some information we just received from Pfizer: 

• Pfizer’s COVID-19 vaccine candidate is 95% effective against COVID-19 beginning 28 days after the first dose 
• We expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021 
• We plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the glob 
• Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
• Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
• Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
• Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world

One of Pfizer’s facilities in the manufacturing and supply chain is located in Andover, Mass.